AbbVie Launches PRODUODOPA® in the EU for Advanced Parkinson’s Disease
AbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read moreAbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb and Karuna Therapeutics, Inc. (“Karuna”) have announced that they have entered into a
Read moreAlzheimer’s disease (AD) and Parkinson’s disease (PD) stand as the two most prevalent neurodegenerative disorders, each characterized by the cerebral
Read moreIn the neurobiology landscape, the Tau protein plays a crucial role in stabilizing microtubules within neurons. Positioned primarily in axons
Read moreStressMarq Biosciences, a market leader and pioneer in the field of fibrilized and oligomeric protein preparations for neurodegenerative disease research,
Read moreStressMarq Biosciences, a pioneer in the development and commercialization of unique fibrilized and oligomeric protein preparations to propel the study
Read moreA collaboration between StressMarq Biosciences and Gubra has generated a 3D whole-brain light sheet fluorescence imaging model depicting alpha-synuclein pSer129+
Read moreStressMarq manufactures and offers a wide range of products specifically developed to accelerate Parkinson’s disease research. StressMarq’s cutting-edge product range
Read moreIn a recent scientific commentary, Brenda Knox at StressMarq delves into the complex interplay between amyloid-beta plaques and tau neurofibrillary
Read moreStressMarq Biosciences, a prominent leader in the field of neurodegenerative disease research products, is excited to announce its participation in
Read more